Aptahem AB Logo

Aptahem AB

A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö

Description

Aptahem AB is a clinical-stage biotechnology company focused on developing aptamer-based pharmaceuticals for acute, life-threatening conditions. The company's technology utilizes aptamers, which are synthetic RNA-based molecules that can serve as an alternative to antibodies. Its lead candidate, Apta-1, is in clinical development for the treatment of sepsis and other critical inflammatory conditions involving a combination of coagulation, inflammation, and tissue damage. Apta-1 is designed with a multi-mechanistic profile to address the complex pathophysiology of these diseases, targeting a significant unmet medical need for which there are currently no effective specific treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Rafael Holdings, Inc. Logo
Invests in and develops therapies for cancer and rare genetic disorders.
United States of America
RFL
Rain Enhancement Technologies Holdco, Inc. Logo
Develops ionization-based weather modification technology for rainfall generation.
United States of America
RAIN
Rallybio Corp Logo
A clinical-stage biotech company developing therapies for severe and rare diseases.
United States of America
RLYB
RaQualia Pharma Inc. Logo
Develops and out-licenses innovative small molecule drug compounds.
Japan
4579
RECURSION PHARMACEUTICALS, INC. Logo
A clinical-stage company applying AI and machine learning to drug discovery.
United States of America
RXRX
RELMADA THERAPEUTICS, INC. Logo
Clinical-stage biotech developing therapies for bladder cancer and compulsive disorders.
United States of America
RLMD
RenovoRx, Inc. Logo
A clinical-stage company developing targeted oncology therapies for solid tumors.
United States of America
RNXT
Repare Therapeutics Inc. Logo
A clinical-stage oncology company developing targeted cancer therapies.
United States of America
RPTX
Replimune Group, Inc. Logo
A clinical-stage biotech developing oncolytic immunotherapies to treat cancer.
United States of America
REPL
ReproCELL Incorporated Logo
Provider of stem cell technology and services for research and regenerative medicine.
Japan
4978

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.